The Practice of Providing Palliative Care in the Situation of the COVID-19 (Coronavirus Disease 2019) Pandemic in Czech Republic (PEOpLe-C19)

October 14, 2021 updated by: Jan Malaska, Brno University Hospital

The Practice of Providing Palliative Care in the Situation of the COVID-19 (Coronavirus Disease 2019) Pandemic in the Perspective of Physicians and Nurses - Survey Study

Pandemic of coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2) causing the disease COVID-19 (Coronavirus Disease 2019) overwhelmed healthcare and brought new challenges and stressful situations.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In a short time, the capacities of intensive care units (ICU) were filled in many countries and regions. Due to the need for an excessive number of patients requiring intensive care, physicians and nurses who do not routinely provide care to critically ill patients or do not have the appropriate training (non-ICU clinician) were involved in the care of COVID-19 (Coronavirus Disease 2019) patients. In this context, ICU directly dedicated to the care of patients with COVID-19 ARDS (Acute Respiratory Distress Syndrome) were also opened. Non-ICU clinicians were more or less involved together with the standard ICU staff in palliative care, including End-of-Life decision (EOLD) making, even in a situation of limited scarce resources (equipment or personnel). New workplace and scope of work, which did not correspond to the standard activity or education, most likely led to an increased stress load. EOLD can also be one of the factors leading to increased stress levels. The aim of the project is to describe the practice of palliative care for patients with COVID-19 in a situation of pandemic COVID-19 and to identify factors leading to possible moral distress related with EOLD.

Study Type

Observational

Enrollment (Actual)

307

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Czechia
      • Brno, Czechia, 62500
        • University Hospital Brno

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Healthcare providers (physicians and nurses) providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic.

Description

Inclusion Criteria:

  • Healthcare providers (physicians and nurses) providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic.

Exclusion Criteria:

  • Healthcare professionals who did not managed COVID-19 patients admitted at the ICU in situation of COVID-19 pandemic in the period 2020/2021.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Physicians
Physicians managing patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
Other: Questionnaire Survey
Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
Nurses
Nurses providing care to patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
Other: Questionnaire Survey
Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of practice of providing palliative care at ICU in COVID-19 pandemic
Time Frame: Through study completion, an average of 1 month
Change of practice of providing palliative care including EOLD practice in patients with COVID-19 admitted at ICU during pandemic.
Through study completion, an average of 1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Risk factors for moral distress
Time Frame: Through study completion, an average of 1 month
Identify factors leading to moral distress during COVID-19 pandemic and describe possible different risk factors by profession
Through study completion, an average of 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Brno University Hospital

Collaborators

Masaryk University

Investigators

  • Principal Investigator: Tereza Prokopová, M.D., Masaryk University Brno

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 21, 2021

Primary Completion (Actual)

October 14, 2021

Study Completion (Actual)

October 14, 2021

Study Registration Dates

First Submitted

May 28, 2021

First Submitted That Met QC Criteria

June 1, 2021

First Posted (Actual)

June 2, 2021

Study Record Updates

Last Update Posted (Actual)

October 19, 2021

Last Update Submitted That Met QC Criteria

October 14, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PEOpLe-C19 study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Questionnaire Survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe